Obseva SA (NASDAQ:OBSV) – Wedbush boosted their FY2018 earnings per share (EPS) estimates for Obseva in a research note issued on Tuesday, November 13th. Wedbush analyst L. Moussatos now forecasts that the company will post earnings of ($1.93) per share for the year, up from their prior estimate of ($2.00). Wedbush currently has a “Buy” rating and a $34.00 target price on the stock. Wedbush also issued estimates for Obseva’s Q4 2018 earnings at ($0.49) EPS, Q1 2019 earnings at ($0.47) EPS, Q2 2019 earnings at ($0.45) EPS, Q3 2019 earnings at ($0.45) EPS, Q4 2019 earnings at ($0.45) EPS, FY2019 earnings at ($1.82) EPS, FY2020 earnings at ($2.21) EPS, FY2021 earnings at ($2.84) EPS and FY2022 earnings at ($1.97) EPS.
Obseva (NASDAQ:OBSV) last posted its quarterly earnings results on Thursday, November 8th. The company reported ($0.42) EPS for the quarter, topping the consensus estimate of ($0.46) by $0.04.
Shares of OBSV opened at $12.91 on Friday. The stock has a market capitalization of $514.11 million, a P/E ratio of -5.74 and a beta of 1.75. Obseva has a 12-month low of $9.05 and a 12-month high of $20.35.
Institutional investors and hedge funds have recently bought and sold shares of the stock. US Bancorp DE acquired a new stake in shares of Obseva during the second quarter valued at $197,000. United Services Automobile Association acquired a new stake in shares of Obseva during the third quarter valued at $206,000. Tiverton Asset Management LLC acquired a new stake in shares of Obseva during the second quarter valued at $224,000. Dimensional Fund Advisors LP acquired a new stake in shares of Obseva during the third quarter valued at $340,000. Finally, Jane Street Group LLC acquired a new stake in shares of Obseva during the second quarter valued at $349,000. 68.34% of the stock is currently owned by institutional investors and hedge funds.
ObsEva SA, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy disorders. It is developing OBE2109, an oral gonadotropin-releasing hormone receptor antagonist for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women; nolasiban, an oral oxytocin receptor antagonist to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization; and OBE022, an oral and selective prostaglandin F2a, or PGF2a receptor antagonist, as a once daily treatment for preterm labor in weeks 24 to 34 of gestational age.
Featured Article: Compound Interest
Receive News & Ratings for Obseva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Obseva and related companies with MarketBeat.com's FREE daily email newsletter.